BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough...
BELLUS Santé inc. (Nasdaq : BLU; TSX : BLU) (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe de nouveaux produits thérapeutiques pour le...
- Announced positive topline results from the Phase 2b SOOTHE clinical trial in refractory chronic cough (“RCC”), positioning BLU-5937 as a potentially best-in-class P2X3 antagonist - - Plans to...
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
4 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
12 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
26 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
52 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
156 | 11.77 | 152.658884565 | 7.71 | 19.9 | 6.3 | 62581 | 12.07293733 | CS |
260 | 10.6 | 119.369369369 | 8.88 | 19.9 | 2.7 | 97406 | 8.60369678 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관